Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK. Motzer RJ, et al. Among authors: narita y. Ann Oncol. 2024 Dec 11:S0923-7534(24)04978-0. doi: 10.1016/j.annonc.2024.12.003. Online ahead of print. Ann Oncol. 2024. PMID: 39672382 Free article.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma.
Hattori K, Makishima K, Suma S, Abe Y, Suehara Y, Sakamoto T, Kurita N, Ishii R, Matsuoka R, Matsuda M, Tsurubuchi T, Nishikawa R, Tanaka S, Mukasa A, Narita Y, Ichimura K, Nagane M, Takano S, Mathis BJ, Ishikawa E, Matsubara D, Chiba S, Sakata-Yanagimoto M. Hattori K, et al. Among authors: narita y. EJHaem. 2024 Nov 14;5(6):1201-1214. doi: 10.1002/jha2.1046. eCollection 2024 Dec. EJHaem. 2024. PMID: 39691244 Free PMC article.
Electromotive field in space and astrophysical plasmas.
Bourdin PA, Narita Y. Bourdin PA, et al. Among authors: narita y. Rev Mod Plasma Phys. 2025;9(1):1. doi: 10.1007/s41614-024-00172-5. Epub 2024 Dec 10. Rev Mod Plasma Phys. 2025. PMID: 39670144 Free PMC article. Review.
Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis.
Ozeki Y, Honda-Kitahara M, Yanagisawa S, Takahashi M, Ohno M, Miyakita Y, Kikuchi M, Nakano T, Hosoya T, Sugino H, Satomi K, Yoshida A, Igaki H, Kubo Y, Ichimura K, Suzuki H, Masutomi K, Kondo A, Narita Y. Ozeki Y, et al. Among authors: narita y. Jpn J Clin Oncol. 2024 Dec 11:hyae151. doi: 10.1093/jjco/hyae151. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39660448
Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study.
Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K, Yamaguchi S, Natsumeda M, Matsutani T, Hanihara M, Nakada M, Kuroda JI, Matsuda M, Yoshimoto K, Yonezawa U, Sonoda Y, Takano K, Yonezawa H, Otani Y, Nakahara Y, Uchida M, Nonaka M, Mineharu Y, Kitamura Y, Yamashita S, Yamauchi T, Miyake Y, Deguchi S, Beppu T, Tamura K, Koizumi S, Hirose Y, Asano K, Hiruta R, Kinoshita M, Miyake K, Nakayama N, Inoue A, Ono T, Sasaki T, Akiyama Y, Fukami S, Yoshino A, Kawanishi Y, Asanome T, Yamaguchi T, Takahashi M, Yamasaki F, Arakawa Y, Narita Y. Kanamori M, et al. Among authors: narita y. Neurooncol Adv. 2024 Nov 28;6(1):vdae176. doi: 10.1093/noajnl/vdae176. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39659832 Free PMC article.
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, Sugimoto N, Minashi K, Imano M, Inamoto R, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K; EN-DEAVOR Study Group. Kawakami H, et al. Among authors: narita y. Gastric Cancer. 2025 Jan;28(1):62. doi: 10.1007/s10120-024-01570-x. Gastric Cancer. 2025. PMID: 39607631 Free PMC article. No abstract available.
967 results